A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Clinical trial NCT07227311 · RECRUITING
Trial details
- NCT number
- NCT07227311
- Sponsor
- GlaxoSmithKline
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-15
- Primary completion
- 2030-08-30
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.